1195995-72-2

Basic information

• Product Name: 2-AMINOPYRIDINE-4-BORONIC ACID PINACOL ESTER
• Synonyms: 2-AMINOPYRIDINE-4-BORONIC ACID PINACOL ESTER;4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine;4-(4,4,5,5-TetraMethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-ylaMine;4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine, 2-Amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine;2-AMinopyridine-4-boronic acid pinacol este;4-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine;2-AMINOPYRIDINE-4-BORONIC ACID PICOL ESTER;4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine HCl salt 97%
• CAS NO: 1195995-72-2
• Molecular Formula: C11H17BN2O2
• Molecular Weight: 238
• Product Categories: Medical Intermediates
• Mol File: 1195995-72-2.mol

Chemical Properties

• Boiling Point: 364.8±27.0 °C(Predicted)
• Appearance: Colorless to pale yellow/Liquid May Contain Few Solid Specs
• Density: 1.09±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 6.28±0.14(Predicted)
• CAS DataBase Reference: 2-AMINOPYRIDINE-4-BORONIC ACID PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINOPYRIDINE-4-BORONIC ACID PINACOL ESTER(1195995-72-2)
• EPA Substance Registry System: 2-AMINOPYRIDINE-4-BORONIC ACID PINACOL ESTER(1195995-72-2)

Safety Data

• Statements: 36
• Safety Statements: 26
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 1195995-72-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Aminopyridine-4-borononic Acid Pinacol Ester is used as a key intermediate for the synthesis of bioactive small molecules, which can be utilized in the development of pharmaceuticals for various therapeutic applications.
Used in Rho Kinase Inhibitors:
In the pharmaceutical industry, 2-Aminopyridine-4-borononic Acid Pinacol Ester is used as a reagent in the preparation of indoleand 7-azaindolecarboxamides. These compounds act as Rho kinase inhibitors, which are important for the treatment of various diseases, including cardiovascular and neurological disorders.
Used in CDC7 Inhibitors:
2-Aminopyridine-4-borononic Acid Pinacol Ester also plays a role in the development of 3D pharmacophore model-assisted discovery of novel heteroaryl dihydrothieno-pyridinones. These compounds serve as CDC7 inhibitors, which have potential applications in the treatment of cancer due to their ability to disrupt cell division and DNA replication.

Upstream product

• 84249-14-9 2-amino-4-bromopyridine 
• 73183-34-3 bis(pinacol)diborane 
• 65370-42-5 4-chloro-2-nitropyridine 

Downstream Products

• 1338581-58-0 4-[2-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyridin-2-amine 
• 1567836-91-2 2,4-difluoro-N-(4-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-2-yl)benzenesulfonamide 
• 908268-52-0 7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)imidazo[1,2-a]pyridine 
• 1095708-32-9 N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]carbamic acid 1,1-dimethylethyl ester 

Relevant articles and documents

Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2′-fluoro-3′-(substituted pyridinyl)-7- deschloroepibatidine analogues

2′-Fluoro-3-(substituted pyridine)epibatidine analogues 7a-e and 8a-e were synthesized, and their in vitro and in vivo nAChR properties were determined. 2′-Fluoro-3′-(4″-pyridinyl)deschloroepibatidine (7a) and 2′-fluoro-3′-(3″-pyridinyl)deschloroepibatidi

Transition metal complex, polymer, mixture, composition and organic electronic device

The invention discloses a transition metal complex, a polymer, a mixture, a composition and an organic electronic device. The transition metal complex has a structural general formula represented by achemical formula (1), and is simple to synthesize, novel in structure, relatively good in stability, long in service life and good in light emitting performance; the compound represented by the chemical formula (1) is convenient for realizing an efficient, high-brightness and high-stability OLED device, and a relatively good material option is provided for full-color display and illumination application.

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replicat

Small molecule compound

The invention provides a small molecular compound, The small molecular compound is characterized by having a structure as shown in the following molecular general formula, wherein X1 and X2 are selected from carbon or nitrogen, G1 is a carbon ring or a heterocyclic ring with aromaticity, any one or more hydrogen atoms on the G1 ring are substituted by R1, wherein R1 is selected from nitrogen-containing groups. The small molecule compound can be used as an efficient and specific JAK kinase inhibitor, especially a Tyk2 inhibitor, and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor, or a Tyk2/JAK1 dual inhibitor or a Tyk2/Jak2 dual inhibitor.

Method for synthesizing aminopyridine borate

The invention discloses a method for synthesizing aminopyridine boronate. According to the method, after nitryl-halogenated pyridine is subjected to Suzuki coupling with metal palladium and bis(glycolato)diboron and simple filtration is performed, hydrogen is directly introduced for reduction, and the product is obtained. Through the operation of the method, the situation is avoided that in the product, the other half of bisdiboron removed during coupling and aminopyridine form a complex compound; the obtained product is high in purity and yield.

Imidazo [1,2-a] pyridine-6-boronic acid frequency ester and its derivatives preparation method

The invention discloses preparation methods for imidazole[1,2-a]pyridine-6-boric acid pinacol ester and derivatives thereof. The preparation methods comprise a preparation method for imidazole[1,2-a]pyridine-6-boric acid pinacol ester, a preparation method for imidazole[1,2-a]pyridine-7-boric acid pinacol ester and a preparation method for imidazole[1,2-a]pyridine-8-boric acid pinacol ester. The imidazole[1,2-a]pyridine-6-boric acid pinacol ester and derivatives thereof prepared by using the preparation methods are used in the Suzuki coupling reaction for a coupling reaction with compounds like halides and TfO-R. According to a technical scheme in the invention, the preparation methods have the advantages of high reaction yield, easy purification, suitability for production, etc.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

NICOTINIC RECEPTOR COMPOUNDS

Provided herein are compounds and methods of preparation of compounds that are capable of functioning as agonists or antagonists of a nicotinic receptor. Also provided are pharmaceutical compositions comprising one or more of these compounds, which may further comprise one or more additional therapeutic agents. Further provided are methods of treatment of various conditions that may be responsive to such activity at the nicotinic receptors, such as nicotine dependence.

HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS

The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.